Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
COSNALAP
1 other identifier
observational
1
1 country
1
Brief Summary
The purpose of this study was to investigate the clinical outcomes of patients with locally advanced pancreatic cancer (LA-PC) who underwent surgery after neoadjuvant chemotherapy (NACT) at Asan Medical Center's Department of Hepato-Biliary-Pancreatic Surgery from 2017 to 2020.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFirst Submitted
Initial submission to the registry
May 9, 2023
CompletedFirst Posted
Study publicly available on registry
June 5, 2023
CompletedJune 5, 2023
June 1, 2023
4 years
May 9, 2023
June 1, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
oncologic outcome
overall survival and recurrence free survival according to the groups
3 - 5 years after surgery
Study Arms (3)
locally advanced pancreatic cancer
Locally advanced pancreatic cancer (LA-PC) is classified according to the National Comprehansive Cancer Networks (NCCN) guidelines. Patients with the above conditions underwent surgery after neoadjuvant chemotherapy.
borderline resectable pancreatic cancer
Borderline resectable pancreatic cancer (BR-PC) is classified according to the NCCN guidelines. Patients with the above conditions underwent surgery after neoadjuvant chemotherapy.
resectable pancreatic cancer
Resectable pancreatic cancer (PC) is classified according to the NCCN guidelines. There are no arterial and venous contact with tumor Patients with the above conditions underwent upfront surgery
Interventions
surgery after neoadjuvant chemotherapy
Eligibility Criteria
We retrospectively reviewed records of patients who were diagnosed with resectable, borderline resectable, or locally advanced pancreatic adenocarcinoma between January 2017 and December 2020, at the Department of Surgery, Asan Medical Center, Seoul, South Korea. A total of 1,358 patients were diagnosed with pancreatic ductal adenocarcinoma and treated.
You may qualify if:
- The study population consists of patients who underwent pancreatectomy for pancreatic adenocarcinoma between January 2017 and December 2020
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Asan medical center
Seoul, 05505, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Song Cheol Kim, MD. PhD
Asan Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 9, 2023
First Posted
June 5, 2023
Study Start
January 1, 2017
Primary Completion
December 31, 2020
Study Completion
December 31, 2022
Last Updated
June 5, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share